Schedule 13G ownership disclosure
Protalix BioTherapeutics, Inc.
Security class unavailable · CUSIP: 74365A101
Event date: 2015-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 2.3700%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001178913-16-005016
- Form type
- SC 13G
- Filer
- Delek Group, Ltd.
- CIK
- CIK 1361371
- Filed
- Apr 07, 2016
- Reporting period
- Dec 31, 2015
- Description
- Schedule 13G beneficial ownership